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The importance of the bone marrow microenvironment forming the so-called niche in physiologic hemopoiesis is largely known,
and recent evidences support the presence of stromal alterations from the molecular to the cytoarchitectural level in hematologic
malignancies. Various alterations in cell adhesion, metabolism, cytokine signaling, autophagy, and methylation patterns of
tumor-derived mesenchymal stem cells have been demonstrated, contributing to the genesis of a leukemic permissive niche.
This niche allows both the ineﬀective haematopoiesis typical of myelodysplastic syndromes and the diﬀerentiation arrest,
proliferation advantage, and clone selection which is the hallmark of acute myeloid leukemia. Furthermore, the immune system,
both adaptive and innate, encompassing mesenchymal-derived cells, has been shown to take part to the leukemic niche. Here,
we critically review the state of art about mesenchymal stem cell role in myelodysplastic syndromes and acute myeloid leukemia,
focusing on immune escaping mechanisms as a target for available and future anticancer therapies.
1. Introduction
Bone marrow stromal cells include mesenchymal stem cells
(MSCs), adipocytes, osteoblasts, ﬁbroblasts, endothelial cells,
tissue macrophages, and osteoclasts. Recent evidences sup-
port the notion that patients with myeloid malignancies
may present bone marrow microenvironment alterations in
terms of abnormal hematopoietic-to-stromal cell interac-
tions, relative deﬁciency of hematopoietic growth factors,
and aberrant release of inhibitors [1]. Nevertheless, the level
of MSC involvement in myeloid malignancies remains
controversial. MSC molecular and genetic alterations in this
context have been demonstrated, and cytogenetic abnormal-
ities in MSC derived from myeloid malignancy patients
have been reported [2–4], while other studies [5] failed to
ﬁnd any signiﬁcant quantitative or qualitative alterations
in myelodysplastic syndrome- (MDS-) derived MSCs.
Leukemogenesis is the result of multistep alterations
involving both the genetic and the epigenetic levels; more-
over, the immune system, far to be an innocent bystander,
plays an active role in leukemic immune escaping mecha-
nisms. In addition, it has not been completely elucidated
whether cancer-associated MSCs belong primarily to the
abnormal clone or emerge after leukemic stem cell induced
environmental damage.
We therefore aimed to synthetically describe the state-of-
the-art MSC alterations in myelodysplastic syndromes and
acute myeloid leukemia, focusing on biological evidences
about MSCs pathophysiologic role in immune escape, that
may represent a possible target both for present and future
anticancer therapies.
2. Mesenchymal Stem Cell Physiology
MSCs are adult multipotent cells that can be isolated from
the bone marrow, umbilical cord blood, placenta, or adipose
tissue [6] and represent fundamental actors in the formation,
organization, and function of the hematopoietic niche [7–9].
Given their heterogeneity, the International Society for
Cellular Therapy (ISCT) position statement suggested to
use the term “mesenchymal SCs” only for cells that are plastic
adherent in culture and express CD73, CD90, and CD105,
but not CD14, CD34, CD45, CD79α, and human leukocyte
antigen-D-related (HLA-DR). Moreover, they should be able
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to diﬀerentiate ﬁbroblasts, osteoblasts, adipocytes, and
chondroblasts in vitro [10] and to transdiﬀerentiate tissues
of neuroectodermal origin such as neurons or glial cells.
MSC tissue of origin remains a matter of debate, and both
mesodermal and neuroectodermal embryonal sheets are
possible candidates [11]. The vascular tissues may be con-
sidered as a source of MSCs, as it is well known that marrow
endothelial cells protect and maintain the repopulating
capacities of hematopoietic precursors in vivo [12] and
regulate proliferation and diﬀerentiation by tight spatial
colocalization with perivascular cells [13] and through
E-selectin secretion [14]. Cytokine and chemokine release
[15] and crosstalk molecules expression, such as Jagged1
and CXCL12 [16–18], play important roles in the regulation
of these interactions.
MSCs display systemic immunoregulatory and immuno-
suppressive properties [19–24] and inﬂuence both adaptive
and innate immune responses. One of the immunomodula-
tory mechanisms is the expression of cell surface molecules
with immunosuppressive capacity, such as programmed
death ligand 1 (PD-L1) and Fas ligand, on MSC surface, so
that they are able to directly deliver inhibitory signals to
immune cells expressing PD-L1 and/or Fas, via cell-to-cell
contact mechanisms [25, 26]. In fact, MSCs can repress
Th1 and Th17 polarization [27, 28] via PD-L1 upregula-
tion/constitutive expression [29]. In this context, their
impairment has been implicated in tumor immune escaping,
as described below.
Moreover, it seems that MSCs may inhibit erythropoiesis
in favor of myeloid diﬀerentiation, through soluble factor
production [30], including interleukin (IL) 6, which was
shown to expand myeloid progenitors blocking erythroid
development [31]. In this context, elevated IL-6 and TNFα
levels have been correlated with adverse survival in patients
with acute myeloid leukemia (AML) [32]. Another player
engaged in the niche regulation is the autonomic nervous
system that accompanies marrow blood vessels through
adrenergic ﬁbers. An interaction of adrenergic ﬁbers with
the MSC microenvironment has been described, and dereg-
ulation of this system has been implicated in impaired
hematopoiesis which is a hallmark of several hematologic
diseases [32, 33].
3. Mesenchymal Stem Cell Behaviour in
Myeloid Malignancies
MSC role in MDS and AML, the two overlapping/evolving
models of myeloid malignancies, will be discussed focusing
on these two biological and clinical conditions which,
although very similar and belonging to a unique disease spec-
trum, show deep diﬀerences in both cellular/molecular and
outcome aspects. Recent evidences, reviewed by Pleyer et al.
[34], show that MDS cells are heavily dependent on their
“dysplastic niche.” MDS-derived MSCs display enhanced
supportive capacities for clonal hematopoiesis by decreased
expression of cell surface molecules [35], including CD44
and CD49e (α5-integrin) [36]. Moreover, in patients with
low-risk disease displaying a hypermethylated phenotype,
circulating endothelial precursors are increased and exhibit
downregulation of members of the wingless-int (Wnt) sig-
naling pathway and failure to adequately sustain normal
hematopoiesis [37]. Keeping on with endothelial-associated
MSCs, CD271-positive MSCs are increased in MDS/AML
marrow, especially in low-risk MDS compared to high-risk
MDS or AML, and show higher CXCL12 expression.
CXCL12-expressing cell density, in turn, correlated with
marrow blast counts and disease progression [38]. Finally,
the TGFβ pathway is constitutively activated in marrow
blasts from patients with MDS, suggesting TGFβ implication
in the pathogenesis of the dysplastic niche [39]. As described
for MDS, in AML, MSC-derived endothelial cells are signiﬁ-
cantly increased, especially in cases with rapidly proliferating
disease, further suggesting MSCs derived cell implication in
leukemic niche building. Furthermore, AML blasts have been
shown to modulate endothelial cell expansion, proliferation,
and activation through the upregulation of E-selectin adhe-
sion molecule [40]. AML blasts may then adhere to the
stroma and be sequestered in a quiescent status becoming
chemo-resistant, constituting a pool of residual disease which
will possibly lead relapse [41]. Adhesion and chemotaxis
have been also evaluated in a recent study, where AMLMSCs
fromAML patients showed similar β1 integrin, CD44, CD73,
CD90, and E-cadherin but decreased monocyte chemoattrac-
tant protein-1 levels compared toMSCs from healthy donors.
AMLMSCs showed chromosomal aberrations, but no signif-
icant diﬀerences in gene expression were detected [42].
Moreover, AML MSCs display constitutive TGFβ signaling,
which may be inhibited by the transcription factor FOS
upregulation, and secrete lower levels of IL-6 and granulocyte
macrophage colony-stimulating factor levels, resulting in
diminished supportive capacity for healthy marrow precur-
sors [40]. Keeping on with MSC interaction with AML blasts,
it has been shown that both cells constitutively release several
soluble mediators, and when cocultured normal MSCs had
an antiapoptotic and growth-enhancing eﬀect on primary
human AML cells in 51 unselected AML patients, this was
associated with increased phosphorylation of mTOR and its
downstream targets. The authors concluded that the
cytokine-mediated eﬀect of the MSCs is growth enhance-
ment/apoptosis inhibition [43]. A recent interesting ﬁnding
is that diﬀerent cytogenetic/clinical AML subsets may show
diﬀerences also in MSC niche, as elegantly demonstrated by
Rodrigues Lopes et al., who characterized MSC cytokine
expression in patients with AML with myelodysplasia-
related changes (MRC), a well-recognized clinical subtype
of secondary AML, and de novo AML. They found that
AML-MRCMSCs presented higher IL-6 expression, whereas
de novo AML MSCs presented increased expression of
VEGFA, CXCL12, RPGE2, IDO, IL-1β, IL-6, and IL-32,
and decreased IL-10 expression. Interestingly, IL-32 was
shown to promote stromal proliferation, chemotaxis, and
crosstalk AML blasts [44].
Finally, altered adrenergic regulation is observed in
leukemic niche and this AML-induced neuropathy (i.e.,
sympathetic denervation of marrow arterioles and reduced
sympathetic tone) reinforces leukemia progression through
depletion of arteriole-associated pericytic mesenchymal
cells [45].
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4. MSC Molecular Pathway Alterations in MDS
and AML
As described in murine experimental models, microenviron-
ment molecular alterations may contribute to the induction
of hematopoietic disorders. Some examples are the activat-
ing mutation in β-catenin and the deletion of miRNA pro-
cessor gene DICER1 in osteoblasts that resulted in the
development of MDS and AML in mice [46, 47]. Interest-
ingly, as reported by Diaz de la Guardia et al., marrow
MSCs, although clearly linked to disease activity and treat-
ment outcome, do not carry tumor-speciﬁc cytogenetic/
molecular alterations [48]. Recently, von der Heide et al.
[2] studied genetic, transcriptional, and DNA methylation
alterations in human AML MSCs and observed a nonspe-
ciﬁc mutation pattern with variable frequency of synony-
mous and nonsynonymous single-nucleotide variations as
well as insertions/deletions of speciﬁc genes. Interestingly,
the number of variants per sample lowered from diagnosis
to relapse. The only mutation with high variant allele fre-
quency involved the PLEC gene (R1801Q), encoding the
cytoskeleton linker protein plectin. PLEC mutation analysis
conﬁrmed that it is present at an early stage of AML-MSC
expansion. Genome-wide DNA methylation analysis also
showed globally altered DNA methylation pattern in AML
MSCs. Generally, CpG methylation showed skewing toward
hypomethylation in AML MSCs. Other authors [49] also
reported transcriptional alterations in MDS MSCs using
RNAseq analyses, contributing to multiple pathway deregu-
lation, including adhesion molecules and metabolic path-
ways as well as endocytosis [50–54].
Another process involved in MSC leukemic pheno-
type acquisition is that of autophagy that is responsible
of senescent cell molecule elimination and turn over.
Reduced expression of autophagy genes was found in
human AML blasts, whereas autophagy pathway is upreg-
ulated in blasts from low-risk MDS cases [55–58], suggest-
ing a role in preventing progression to high-risk disease or
AML evolution.
The gene TWIST, a transcriptional regulator contribut-
ing to MSC self-renewal and diﬀerentiation, was shown to
be upregulated in MDS human blasts, and its expression
was demonstrated to be altered by stroma contact and to
correlate with disease stage and p53-mediated apoptosis
[59–61]. In this context, TWIST tumor suppressor func-
tion, exerted by p21 activation, appears epigenetically
silenced by hypermethylation in 31% of adult AML
patients, providing leukemic cells with proliferation and
survival advantages [62].
Finally, Notch/Jagged1 abnormalities have been described
in human MSCs, leading to impaired diﬀerentiation and
plasticity and contributing to MDS pathogenesis [63],
while constitutively active β-catenin expression favored
AML induction in murine models [46]. Moreover, Geyh
et al. [64] showed that MSCs from AML patients exhibit
Kit-ligand and Jagged1 pathway alterations, causing
growth deﬁciency and impaired osteogenic diﬀerentiation
capacity, partially reversible and correlating with a dis-
ease status.
5. MSCs and Tumor Immune Escape
5.1. Immune System in Myeloid Malignancies: A Naive
Surveillant? Innate and adaptive immune pathways demon-
strate aberrant activation in the hematopoietic niche of
MDS playing a role in the increased rate of apoptosis of mar-
row precursors which is the hallmark of marrow failure.
Moreover, an increased incidence of autoimmune diseases
(e.g., primary immune thrombocytopenia, vasculitis, hypo-
thyroidism, and rheumatoid arthritis) in patients with MDS
has been reported in epidemiological studies [65], and
recently, [66] the existence of a spectrum of pathophysiologic
entities, spanning from chronic autoimmune attack to frank
MDS and AML, through idiopathic cytopenia/dysplasia of
undeterminate signiﬁcance (ICUS/IDUS), has been hypothe-
sized. Focusing on cellular immunity, naïve T cells (CD3+)
exhibit shorter telomere length and have signiﬁcantly less
proliferative potential in MDS than in normal controls; oli-
goclonal T cells, often derived from the malignant MDS
clone, may be present and seem to inhibit hematopoiesis
in vitro, possibly through MHC class I molecules targeting
on benign and malignant hematopoietic precursors, as a part
of tumor surveillance. As the targeting of these mechanisms
through immune-suppressive therapies has not been associ-
ated to AML progression, it is thought that MDS cells escape
immune patrolling through a cytokinic permissive stromal
pattern. These aspects are also shared byaplastic anemia,
another genotypical (as these patients harbor mutation char-
acteristic of MDS and ICUS/IDUS in almost half of cases)
and phenotypical models bridging autoimmunity and malig-
nancy, in which T cell-mediated marrow suppression leads to
bone marrow failure with an increased risk of AML evolution
[67]. Altogether, these alterations may reduce the “naive”
immune surveillance on malignant transformation, modulat-
ing those mechanisms that, although various and articulated,
may be eluded. In MDS patients, an increased expression of
inﬂammatory T helper 1 cytokines has been reported, con-
tributing to systemic symptoms and increased apoptosis
[67]. In particular, tumor necrosis factor alpha (TNF-α)
overexpression is inversely correlated to hemoglobin and
survival, as it favors Fas-mediated- and TNF-related
apoptosis-inducing ligand- (TRAIL-) driven ineﬀective
hemopoiesis. Moreover, IFN regulatory factor 1 (IRF-1)
mRNA, a tumor suppressor gene involved in T cell matura-
tion and inﬂammatory responses, has been found upregu-
lated in MDS patients with autoimmune phenomena
compared to those without [68, 69]. Transforming growth
factor-β (TGF-β) has been implicated in MDS hemopoietic
suppression directly or mediated by the production of other
myelosuppressive cytokines (e.g., IL-6, IL-32, IFN-g, and
TNF), leading to decreased B cell proliferation, natural killer
dysfunction, and propagation of cell autophagy or apoptosis.
Inhibition of TGF-β receptor I kinase was shown to decrease
apoptosis and improve erythroid and myeloid colony forma-
tion in vitro. T-helper 17, involved in the development/pre-
vention of autoimmunity and inﬂammation, is signiﬁcantly
increased in low-risk MDS [69]. Finally, innate immunity is
highly active in MDS cases due to overexpression of TLR
activators, such as MYD88, TIRAP, IRAK1/4, and TRAF,
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and downregulation of inhibitory factors, such as micro-
RNAs miR145 and miR146a [70].
In AML, the immune system may play a role in enabling
blast proliferation originating from the leukemic stem cell
which in turn escapes surveillance. Cellular-mediated
immune killing is driven by T CD8+ recognition of aber-
rant/exogenous molecules presented on MHC Class I
complex, and the loss/mutation of MHC Class I is a demon-
strated escape strategy in solid tumours. In AML, MHC Class
I loss is rare, but allows NK cells to escape through killer cell
immunoglobulin-like receptors (KIR). Moreover, expression
of nonclassical HLA molecules, as reported for soluble HLA-
G detected in AML sera, may contribute to immune suppres-
sion. CD4+ T cells and antibody-driven immunity rely on
MHCClass II recognition of presented extracellular antigens;
these molecules present variable expression on AML cells,
and their total loss on promyelocytic leukemia cells may rep-
resent a possible escaping strategy. Currently, great interest is
being given to AML-associated antigens (e.g., antigens aber-
rantly expressed by AML cells) that may elicit immune
responses. For example, Wilms’ tumour protein 1 (WT1), a
zinc ﬁnger transcription factor overexpressed in AML cases,
especially in leukemic stem cells, provides a target to elimi-
nate the quiescent neoplastic cells. Moreover, some AML-
speciﬁc genetic alterations may lead to aberrant antigen
recognition through both MHC Classes I and II, as observed
for FLT3-ITD, PML-RARalpha, BCR-ABL, DEK-CAN, and
NPM1 mutations. As described for MDS, both innate and
adaptive immunities are eluded by AML blasts through dif-
ferent mechanisms: (1) suppression of NK cell-mediated
cytotoxicity by the inability to lyse AML cells, production
of cytotoxic cytokines, aberrant expression of VEGFC, and
by immature NK cell inhibition of T cell activation. (2) T cell
suppression through aberrant gene expression in T cells,
through the inability to form eﬀective immune synapses with
AML blasts, and by the coexpression of immunosuppressive
proteins (TIM-3 and PD-13). Higher proliferation of Tregs
facilitates blast expansion by T eﬀector cell suppression
through secretion of immunosuppressive cytokines (e.g.,
TGF-beta). In addition, Tregs increase the production of
adenosine, an immunosuppressant for T and NK cells. (3)
Secretion/expression of immunosuppressive factors by
AML cells, including indoleamine 2,3-dioxygenase 1 (IDO)
expression, arginine metabolism, and secretion of reactive
oxygen species [71]. It is noteworthy to mention that immu-
nologic milieu in AML is dynamic, as it is altered and modu-
lated not only by the disease itself, but even by therapeutic
interventions. As a matter of fact, AML in remission after
chemotherapy shows decreased innate (neutrophils and
monocytes) and speciﬁc immune activities (B cell activation)
and cytokine pattern may also be changed. Even deeper is the
change after allogeneic transplant, where immune reconsti-
tution is a long and complicated process implying the adop-
tion/maturation of the donor immunocompetent cells and
the persistency of the recipient memory cells. In a recent
study, evaluating the functional capacity of the immune sys-
tem in 10 adult patients with AML using the response to sea-
sonal inﬂuenza vaccination as a surrogate, only 2 patients
generated protective titers in response to vaccination and a
majority of patients had abnormal frequencies of transitional
and memory B cells, with B cell repertoire showing little evi-
dence of somatic hypermutation. Conversely, T cell popula-
tions were similar to healthy controls, and cytotoxic T cells
demonstrated antigen-speciﬁc activity after vaccination, with
T-eﬀector cells showing increased PD-1 expression with pos-
sible therapeutic implications (see speciﬁc paragraph) [72].
5.2. MSCs Interact with Microenvironment Immunologic
Landscape. MSCs have immunoregulatory activities exerted
by interaction with a large number of eﬀector cells, including
T cell subsets, B cells, NK cells, monocyte-derived dendritic
cells, and neutrophils, by direct cell-to-cell adhesion and/or
secretion of soluble molecules, the so-called MSC secretome,
which includes soluble molecules and extracellular vesicles
(EVs) released by the MSCs into the extracellular milieu.
Moreover, terminally diﬀerentiated mesenchymal cells pre-
vent both proliferation and apoptosis of activated T cells.
MSC-mediated immune regulation encompasses several
mediators including interferon-γ (IFN-γ), interleukin-1β
(IL-1β), transforming growth factor-β1, indoleamine-2,3-
dioxygenase (IDO), IL-6, IL-10, prostaglandin-E2, hepato-
cyte growth factor, tumor necrosis factor (TNF)-α, nitric
oxide (NO), heme oxygenase-1, and HLA-G5. These sug-
gest a wide variety of targets for both immune inhibition
and escaping mechanisms. Concerning innate immunity,
MSCs are able to inhibit neutrophil proinﬂammatory
activities suppressing the respiratory burst and prolonging
survival through IL-6 and STAT-3 pathways. Moreover,
they inhibit mature DC diﬀerentiation while promoting
IL-10-producing plasmacytoid DCs. In a recent report,
bone marrow MSCs were able to inhibit mouse DC activity
by decreasing expressions of TLR3 and TLR9, conﬁrming
the immunomodulatory role of MSCs in a cell-based therapy
[73]. Finally, MSCs suppress NK proliferation, soluble factor
production, and cytotoxic activity. As long as adaptive
immunity is concerned, MSCs promote quiescent T cell sur-
vival, but induce anergy of activated T cells and inhibit pro-
liferation in favor of Tregs development driven by IL-10
secretion. B cell proliferation/diﬀerentiation is also sup-
pressed both directly and through activated CD4+ T cell sup-
pression. These immunoregulatory properties are exerted
both directly and through MSC-derived exosomes, which
have been used for therapeutic purposes as later discussed
[74]. The abilities of MSCs to modulate immune responses
may contribute to their therapeutic activity in models of
autoimmune/inﬂammatory disorders. As an example, in
rheumatoid arthritis, human adipose tissue-derived MSCs
were able to inhibit IL-17 and IL-21 secretions by mononu-
clear cells and to increase TGF-β expression with consistent
immunomodulatory eﬀects [75].
5.3. MSCs Contribute to Leukemia Permissive Niche Also by
Immune-Mediated Mechanisms in Lymphoid and Myeloid
Models. Tumor microenvironment is thought to be inﬂam-
matory and “educated” by the neoplastic cells to be permis-
sive in favor of the neoplastic clone growth. MSCs from the
neoplastic niche are then in turn able to switch their pheno-
types from MSC Type 1 (proinﬂammatory) to “tumor-
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educated”MSC Type 2 cells (anti-inﬂammatory) that exhibit
stronger immunosuppressive and migratory properties and
drug resistance and promote proliferation [76, 77]. Interest-
ingly, transcriptome proﬁling assays revealed a proinﬂamma-
tory signature in bone marrow MSCs, with deregulation of
immune and inﬂammatory modulators of the prostaglandin
synthesis, largely depending on the genomic instability char-
acteristic of oncogenic transformation, which is more typical
of solid tumor than of AML, that is known to show limited
number and type of identiﬁable driver/passenger mutations
[78, 79]. The phenomenon of epithelial to mesenchymal
transition, typical of solid tumors and linked to metastatiza-
tion ability, is another evidence of mesenchymal contribution
to tumor escape: malignant epithelial cells modify their tran-
scriptional programme losing cell–cell attachments and
acquiring mesenchymal-like features and motility, through
deregulation of molecular pathways that include TGFβ,
Wnt, Notch, hedgehog, and tyrosine kinase receptors. This
phenotype has been associated in solid tumors with poor
prognosis and resistance to radio- and chemotherapy. A
minority of these mesenchymal-switched-circulating tumor
cells migrate and survive in the bloodstream, evading
immune surveillance, extravasate, and are able to colonize
target organs or tissues [79]. Similarly, chronic lymphocytic
leukemia-derived exosomes actively promote disease pro-
gression by modulating several functions of surrounding
stromal cells that acquire features of cancer-associated
ﬁbroblasts. More in details, CLL-derived exosomes are
actively incorporated by endothelial and mesenchymal stem
cells that show enhanced proliferation, migration, and
secretion of inﬂammatory cytokines, contributing to a
tumor-supportive microenvironment [80, 81]. Cancer-
associated MSCs have greater chemotactic activity on
mononuclear cells and Tregs and inhibit T cell cytotoxicity
and B cells and NK cells, as observed in solid and hemato-
logic malignancies [82–85]. As mentioned above, MSCs
secrete IDO and PGE2. The IDO enzyme activates dendritic
cells and macrophages, helping to create an environment
that favors suppression and tolerance. This molecule has
been shown to play a relevant role in promoting solid/liquid
tumor tolerance in vitro and in vivo murine models
[86–88]. In addition, many human tumors have been shown
to produce IDO [89]. In a recent report, MSCs isolated
from 20 bone marrow AML samples showed higher expres-
sion of IDO and increased Tregs compared to control sub-
jects, with a positive correlation between IDO expression
and Tregs, responsible for immunosuppressive microenvi-
ronment [90]. Neoplastic MSCs in MDS and AML decrease
tumor immunosurveillance through downregulation of
costimulatory molecules (CD40, CD80, and CD86) [91],
increase immunosuppressive cytokine production (TGFβ,
IL-6, and HGF) with consequent T cell and DC suppression
and Tregs and MSC type 2 increases. These alterations
are more markedly observed in high-risk than in low-
risk MDS [92, 93]. Constitutive overexpression of IDO
observed in AML blast cells and sera [94] correlates with
decreased relapse-free and overall survival [95]. Moreover,
high IDO levels in MDS cases correlate with cytopenias
severity [96].
Recent evidences support the role of T helper (Th) cells in
the pathogenesis of hematological malignancies, including
Th1/Th2 unbalance, increased Treg and Th17 levels, as well
as the recently identiﬁed Th22 cells, that produce IL-22,
which belongs to IL-10 cytokine family involved in the
pathogenesis of autoimmune diseases and MDS. Tian et al.,
studied T helper subsets in AML patients and found that,
while Th1, Th2, Th17, and Th22 cells and IL-22 were signif-
icantly reduced, Treg cells were increased in newly diagnosed
AML patients compared to patients in remission or controls
and chemotherapy ameliorated these variations [97]. MSC-
mediated alteration of immune environment may be revers-
ible with leukemia treatment, as also shown in patients with
juvenile myelomonocytic leukemia, whose MSCs showed
diﬀerential mRNA expression, including genes involved in
immunomodulation and cell–cell interaction, that normal-
ized during remission after successful hematopoietic stem
cell transplantation [98].
As far as innate immunity is concerned, coculture of
AML cells with MSC signiﬁcantly protects leukemic blasts
from NK cell-mediated lysis, mainly through cell-to-cell con-
tact with supportive MSC, implying a relevant role of MSC in
the immune response against AML blasts [99]. Moreover,
overexpression of toll-like receptor- (TLR-) regulated genes
has been described in MDS, resulting in excessive apoptosis
with consequent cytopenias and decreased erythropoiesis in
lower risk stages. In fact, TLR1, 2, and 6 expressions are
higher in CD34+ blasts from patients with lower risk
compared to higher risk MDS, whereas TLR2 and 4 expres-
sions were similar in AML patients and healthy controls
[100–102]. Concerning clinical correlations, higher expres-
sion of TLR2 is associated with prolonged survival, whereas
higher expression of TLR6, TLR7, and MYD88 (a key medi-
ator of TLR signaling) might confer a worse prognosis. On
the contrary, in AML, stimulation of TLR2 and 4 resulted
in induction of immune escape mechanisms such as upregu-
lation of PD-L1, which protected AML cells from cytotoxic T
lymphocyte lysis in vitro [103, 104]. Finally, recent evidences
also show antileukemic eﬀects for TLR8 activation, indepen-
dently from its immunomodulating properties [105].
On the contrary, in lymphoid malignancies, a host
beneﬁcial immunomodulatory eﬀect mediated by MSCs has
been shown in low/intermediate risk acute lymphoblastic
leukemia patients, where MSCs promoted an eﬃcient NK
cell response including cytokine production, phenotypic
activation, and cytotoxicity [106].
Recently, Giallongo et al. identiﬁed a population of
myeloid-derived suppressor cells (MDSC) in chronic mye-
loid leukemia (CML) patients that is part of the tumor clone
and provides a leukemic friendly microenvironment medi-
ated by ARG1, NOS2, reactive species of oxygen (ROS),
cyclooxygenase 2 (COX2), TGFβ and immunosuppressive
cytokine production, inhibition of NK function, and Treg
expansion.WhenMSC-educatedMDSC fromhealthy donors
and CML patients were generated by coculturing MSC with
peripheral blood-mononucleated cells, only CML-MSC-
educatedMDSC exhibited a suppressive ability on autologous
T lymphocytes and overexpressed TGFβ, IL-6, and IL-10,
thus contributing to CML immune escape [107].
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6. Mesenchymal Stem Cells:
Therapeutic Implications
6.1. Targeting Immune Escape. The immune disregulation of
the dysplastic and leukemic niches is an interesting target for
biological therapies. Recently, growing evidences support the
use of immune checkpoint blockers as well as engineered
immunocompetent cells and monoclonal antibody therapies
engaging speciﬁc T cells in hematologic malignancies.
Immune checkpoints are regulatory pathways that are
induced in activated T cells and regulate the amplitude as
well as the quality of T cell antigen responses. However, can-
cer can exploit these immune cell-intrinsic checkpoints for
escaping immune-mediated destruction, by upregulation
and activity of checkpoint molecules on T cells, leading to
reduction or elimination of antitumor immune activity.
CTLA-4 and PD-1 are two of the most actively studied
inhibitory receptors expressed by activated T cells. The
PD-1 pathway not only suppresses functions of eﬀector T
cells, lytic capacity of NK cells and B cell antibody produc-
tion, but also promotes Treg stability and functions, thus
contributing to the maintenance of immune suppression
in the microenvironment. PD1/PDL1 upregulation may be
targeted with immune checkpoint blockers. As a matter of
fact, immune checkpoint inhibitors may enhance cytotoxic-
ity of cytokine-induced killer cells against human myeloid
leukaemic blasts [108], suggesting that also AML may ben-
eﬁt from checkpoint inhibition, as it has been demonstrated
in solid cancers.
In a recent study, vaccination with MSCs exposed to
microgravity inhibited proliferation and promoted apoptosis
of tumor tissue, by inducing Th1-mediated cytokine
response and CD8-dependent cytotoxic response and by
increasing MHC1 and HSP protein expressions. The
enhanced antitumor immune response of MSCs was strongly
associated with the higher expression of MHC class I mole-
cule on DCs that made tumor molecules more cross-
presentable to the host DCs to generate protective antitumor
activity [109].
Another interesting approach consisted in the adoptive
transfer of gene-modiﬁed MSCs, which produce and secrete
tumor-directed monoclonal antibodies continuously in the
body of the patient, as bispeciﬁc autoantibodies have short
half-lives in vivo and are rapidly cleared from circulation.
As MSCs have limited immunogenicity and tend to accumu-
late in close proximity of the tumor, they can be used as a
platform for the targeted delivery of anticancer agents.
Aliperta et al. recently demonstrated that gene-modiﬁed
MSCs are able to express the CD33-CD3 bispeciﬁc antibody
at high levels and to mediate an eﬃcient lysis of AML blasts
by human T cells of both healthy donors and AML patients
[110]. The same mechanism was explored in a murine model
of disseminated ALL, to selectively deliver measle virus to
leukemic cells [111]. As regards leukemic MSC role in
adapted immunity, they seem to favor chemotaxis of mono-
nuclear cells and Tregs and to inhibit T cell cytotoxicity and
B cell and NK cell activities, possibly through the secretion of
IDO and PGE2 [86]. This observation may provide a further
rationale for the use of IDO inhibitors in myeloid
malignancies. Recently, Ninomiya et al. showed that tumor
microenvironment suppresses chimeric antigen receptor T
(CART) cell activity through IDO immune escape in a xeno-
graft lymphoma model. Moreover, they report that ﬂudara-
bine and cyclophosphamide downregulate IDO expression
and improve CART antitumor activity [112].
MSCs of MDS overexpress TLR-regulated genes, result-
ing in excessive apoptosis with consequent cytopenias and
decreased erythropoiesis. Preliminary in vitro observations
favour the rationale of targeting aberrant TLR signaling in
this setting [113]. Furthermore, TLR2 and 4 are upregulated
in AML, resulting in induction of immune escape mecha-
nisms such as upregulation of PD-L1, which protects AML
cells from cytotoxic T lymphocyte [114], with a negative
prognostic impact. Consequently, TLR agonists have been
used as immunotherapy with the intent of inducing blast-
derived dendritic cell maturation, both in vitro [115–119]
and in clinical trials [120].
As regards antibodies and antibody-derived agents such
as antibody drug conjugates and bispeciﬁc agents, CD33 is a
valuable and clinically validated target; a prototypical agent,
gemtuzumab ozogamycin, was shown to be eﬀective in AML
treatment, but was withdrawn from the clinical use because
of side toxicities, mostly due to the chemical linker connecting
the toxin component to the antibody carrier, even if in early
2017 a new request for US and EU approval was submitted.
Moreover, antibodies speciﬁc for CD123 are under evaluation
and seem to target the leukemia stem cells. New CD33-
directed agents include new toxins coupled with improved
linkers to the antibody (e.g., SGN-CD33a), bispeciﬁc antibod-
ies recruiting eﬀector cells likeNKs or T cells (e.g., AMG-330),
and single-chain triplebodies (e.g., 123–16-33 and 33–16-33)
with a double receptor for the AML blast and one recruiting
NKs. Immune reconstitution has a key role in enabling
immune-mediated therapies in AML patients in remission
to eliminate leukemic stem cells and MRD. NKs recovered
from AML patients at diagnosis are often reduced and show
reduced cytolytic activity; a recent study compared blood
titers and cytolytic function of NKs from anAMLpatient with
those of a healthy monozygotic twin. The Authors found that
NK functions measured in the AML patient after disease
remission were comparable to those of his healthy twin
brother; moreover, ex vivo cytolytic activities mediated by tri-
plebody SPM-2 were also maintained, making triplebodies
promising new agents for the treatment of AML [121].
Graft versus host disease (GVHD) has been one of the
autoimmune targets for MSC therapies in mouse models.
These models are unfortunately diﬀerent from the human
counterparts as murine MSCs are more prone to spontane-
ous immortalization and transformation and IDO is not
involved in mouse MSC-mediated immunoregulation. In
mice, a single infusion of MSCs at the time of transplant does
not prevent GVHD, whereas multiple injections may be ben-
eﬁcial, and engraftment of MSCs at GVHD sites is low. MSC
cotransplantation does not promote engraftment in T cell-
replete transplants, but might be beneﬁcial in T cell-depleted
transplants. MSC treatment of corticosteroid-refractory
acute GVHD showed controversial results in human, with a
European trial providing 30 out of 55 complete responses,
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whereas another study failed to demonstrate any durable
beneﬁt. Recently, a phase II randomized study showed that
repeated infusion of MSCs may inhibit chronic GVHD
symptoms and reverse the Th1/Th2 cell ratio imbalance [74].
An interesting therapeutic approach is adoptive immu-
notherapies in myeloid malignancies that include, among
others, bone marrow allogeneic transplant, donor lympho-
cyte infusion (DLI), and chimeric antigen receptor T (CART)
cells [122]. These approaches are currently aimed at leukemic
blast targeting, but MSC patterns might be new targets in the
next future. In particular, CART cells, engineered with syn-
thetic polypeptides consisting of an extracellular variable
fragment directed to a tumor antigen and an intracellular sig-
naling domain, potentiated by the addition of costimulatory
molecules in new generation models, have shown great suc-
cess in relapsed/refractory ALL and may ﬁnd a role in AML
too, possibly targeting AML-associated/speciﬁc antigens like
CD33, CD123, Lewis Y antigen, and folate receptor beta
[123]. DLI is eﬀective in reinducing response in AML resid-
ual/relapsing disease after allogeneic stem cell transplant
and is currently investigated as a way to eradicate minimal
residual disease (MRD), which correlates to higher relapse
rate and reduced survival in AML [124].
Considering MDS, the therapeutic eﬃcacy of lenalido-
mide is of great interest and is being moved from 5q syn-
drome to all low-risk cases. The drug, while directly
inducing proliferation inhibition and apoptosis of MDS
cells, plays important immunomodulatory activities by
inducing T cell-mediated cytotoxicity, through CD28 costi-
mulation and interferon-γ- and interleukin-2-increased
productions, and by NK cell activation. At the same time,
lenalidomide decreases inﬂammation by inhibiting the pro-
duction of proinﬂammatory cytokines such as TNF-alfa
and interleukin-1,-6,-12 and eliciting anti-inﬂammatory
cytokine release, like interleukin-10, thus contrasting the
inﬂammatory microenvironment that is detrimental to
normal hematopoiesis [125].
6.2. Other MSC-Related Targets. The observation that cell-to-
cell contact is necessary for “stemness” maintenance has led
to the evaluation of adhesion mechanisms as possibly target-
able players in malignant bone marrow milieu. In this con-
text, signaling pathway of adhesion protein HSP90α/β has
been shown to give proliferative advantage to MDS MSCs
in patients with advanced-stage MDS, [126] being a potential
therapeutic target in MDS. A recent study demonstrated the
inhibitory eﬀects of BIIB021, an orally available Hsp90 inhib-
itor, on an imatinib-resistant chronic myeloid leukemia cell
lines, with signiﬁcant growth inhibition and apoptosis and
autophagic response [127]. HSP90 also safeguards proteins
and is deacetylated by histone deacetylases 6; recent data
show that histone deacetylase inhibitor-induced acetylation
of HSP90 might control oncologically relevant proteins,
especially in leukemic cells [128]. Moreover, various experi-
ments indicate that [129, 130] CD44 adhesion pathway is of
great interest in human AML and therapeutic blocking of this
molecule in AML cells has been evaluated in murine xeno-
grafts, with some promising results [131]. For example, Li
et al. reported that the anti-CD44 monoclonal antibody
A3D8 inhibited proliferation of acute leukemia cell line HL-
60. The A3D8 treatment increased the percentage of G0/G1
cells [132]. However, other in vitro experiments showed that
MSCs may escape this targeted therapy and that leukemic
stem cells become less microenvironment dependent in
advanced-stage AML, so that targeting of CD44 may be less
successful than expected. Anyway, some phase 1 trials are
testing antibody against CD44v6 (bivatuzumab mertansine)
in solid tumors, and MDS/AML setting might be a future
ﬁeld of application [133, 134].
As described in a recent study from von der Heide et al.
[2], plectin, a cytoskeleton linker protein, is highly overex-
pressed in AML BM MSCs and its mutations are present at
diagnosis, at the time of response and at relapse. This protein
is also a biomarker for pancreatic ductal adenocarcinoma
cells and a recent study [135] designed a plectin-1 selective
drug delivery to pancreatic malignant cells. As immunohisto-
chemical staining of plectin in bone marrow showed high
proportion of plectin-positive cells in AML, a rationale may
exist for such therapeutic strategies in this disease too. The
targeted drug delivery that uses MSC for the spatial control
of drug release is a growing ﬁeld that will possibly have
further implication in AML niche-directed therapies.
One of chemotaxis is another potentially targetable path-
way: inhibition of CXCL12 stromal cells, and/or the CXCR4/
CXCL12 axis, has shown promising results in mice and is
currently being explored in clinical trials of MDS and AML
[136–139]. Peng et al. report that a humanized anti-CXCR4
monoclonal antibody, LY2624587, blocked SDF-1 binding
to CXCR4 in human lymphoma and leukemia cells, inhibit-
ing cell migration, cell signaling including activation of
MAPK and AKT, and mediating receptor internalization
and CXCR4 downregulation on the cell surface. LY2624587
caused dose-dependent apoptosis in vitro and in mouse
xenograft models, providing signiﬁcant survival beneﬁt
[140]. Besides receptor antagonists that directly inhibit
leukemic cell proliferation, preclinical and clinical studies
demonstrate that CXCR4 inhibition mobilizes leukemic-
lymphoma cells from their niches, improving conventional
chemotherapy eﬃcacy. An interesting study recently
highlighted that runt-related transcription factor 3 (RUNX3)
is involved in MSC-mediated protection of leukemia cells
fromAs2O3- (arsenic trioxide-) induced apoptosis. In partic-
ular, in the presence of MSCs, As2O3-induced expression of
RUNX3, modulated by CXCL12/CXCR4 signaling, was
reduced. Furthermore, overexpression of RUNX3 restored
the sensitivity of leukemic cells to As2O3. Therefore, RUNX3
is a promising target for therapeutic approaches to overcome
MSC-mediated drug resistance [141].
Again, in the ﬁeld of soluble niche molecules, high levels
of TGFβ are secreted by leukemic MSCs, possibly contribut-
ing to impaired normal hematopoiesis in MDS. The TGFβ
pathway, which is constitutively active in MDS blasts, may
be targeted by speciﬁc inhibitors. Suppression of TGFβ
signaling in murine models and in human bone marrow
samples in vitro was shown to be able to restore normal
myelopoiesis and erythropoiesis [30, 40]. Moreover, Naka
et al. demonstrated the therapeutic eﬃcacy of EW-7197, an
orally bioavailable TGFβ signaling inhibitor, combined with
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tyrosine kynase inhibitors, in eliminating chronic myeloid
leukemia initiating cells in vivo: the combination signiﬁ-
cantly delayed disease relapse and prolonged survival [142].
In another study, TGF-β-transduced MSCs were able to sup-
press T cell proliferation and IFN-γ release and to reduce
expressions of CD40, CD86, and MHC II as well as TNF-α
secretion by dendritic cells, while IL-4 secretion was
enhanced. TGF-β-transduced MSCs could provide a promis-
ing tool for treatment of clinical conditions such as organ
transplantation, GVHD, and autoimmune disorders [143].
As regards DNA methylation in myeloid malignancies,
altered epigenetic modiﬁcations in myeloid blasts are
thought to be highly pathogenetic in these diseases, providing
a rationale for hypomethylating drug use and eﬃcacy. These
drugs form nowadays the backbone for anticancer therapies
in the elderly and in those patients ineligible for intensive
chemotherapy. As a matter of fact, recent studies demon-
strated that leukemic MSCs harbor highly speciﬁc diﬀerences
in methylation patterns in comparison to healthy volunteers,
indicating diﬀerential activity and function of MSCs in these
diseases. In this context, the epigenetically regulated Wnt/
β-catenin pathway was shown to be altered in MSCs from
myeloid malignancies and associated with adverse prognosis
[144–146]. Hypomethylating agents are able to demethylate
Wnt antagonist gene promoters in vitro [147], leading to
Wnt reexpression and normal myelopoiesis restoration.
Similar results were described for the above mentioned gene
TWIST, implicated in the pathophysiology of clonal myeloid
diseases [148], whose reexpression in vitro occurred after
treatment with hypomethylating agents [149]. Regarding
autophagy, which confers a sort of cell protection in lower
risk MDS and becomes defective along with disease progres-
sion, it could be another possible target for hypomethylating
agents. In fact, downregulation of autophagy-associated
genes was shown to be due to promoter hypermethyla-
tion in higher risk MDS and AML, and reexpression of
autophagy-associated genes has been observed in AML cell
lines [55, 56].
7. Conclusions
Current knowledge highlights the importance of a leukemic
permissive bone marrow niche in supporting abnormal
myeloid precursor clonal proliferation. MSC- and MSC-
derived cells show morphologic, cytogenetic, and molecular
abnormalities in myeloid malignancies encompassing cell
adhesion, cytokine signaling, autophagy, and methylation
patterns, leading to and favoring diﬀerentiation arrest,
proliferation, and clonal selection. Moreover, the immune
system, both adaptative and innate, participates in the leu-
kemic permissive milieu and immune escape correlates with
disease relapse and refractoriness to standard therapies.
Finally, these patterns are currently being investigated as
suitable targets for already available and future anticancer
therapies. The development of immune escape-directed
treatments will have to consider the cross-talk between
immune cells and MSCs, particularly considering disease
characteristics, phase (onset, remission, and MRD status),
immune reconstitution, and therapeutic goal.
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